Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Microba Life Sciences Limited ( (AU:MAP) ) is now available.
Microba Life Sciences reported strong growth in its core testing business for the March quarter, with core test volumes up 58% year-on-year and an annualised run rate above 23,000 tests, driven largely by enterprise-style clinic accounts. In Australia, Microbiome Explorer sales rose 49% to a record 4,786 tests and MetaPanel sold 204 tests, while UK Microbiome Explorer volumes surged 232% to 816, closely tracking and outperforming the Australian adoption curve at a comparable stage.
Core testing revenue nearly doubled to $2.1m versus the prior corresponding period, total quarterly revenue was $3.36m, and cash receipts reached $3.98m, with $7.28m in cash or equivalents and the company reiterating guidance to reach regional break-even by the end of FY26. The Invivo supplements business continued to gain traction, with PHGG prebiotic fibre volumes up 161% and more than 800 UK subscribers, as Microba positions itself as a focused testing and supplements company following the discontinuation of legacy products.
Microba highlighted strengthening clinical validation, including a published paper showing high specificity and sensitivity for MetaPanel, supporting uptake through its Sonic Healthcare partnership and reinforcing its scientific credibility with healthcare professionals. In therapeutics, recent positive sector trial readouts, including in inflammatory bowel disease, have bolstered the investment case for Microba’s lead asset MAP-315 and prompted intensified partnering efforts amid rising interest in live microbiome drugs.
The company disclosed that it is in confidential negotiations over a potential significant corporate transaction that, if completed, would improve its financial position and require shareholder approval. Looking ahead, Microba is preparing a major new product launch in early Q1 FY27 aimed at broadening its addressable market to more medical doctors, underscoring its strategy to scale recurring testing revenues and solidify its leadership in the emerging microbiome diagnostics category.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.29 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
More about Microba Life Sciences Limited
Microba Life Sciences Limited is an ASX-listed company focused on microbiome diagnostics and therapeutics, providing advanced gut microbiome testing services and related products. Its portfolio includes the Microbiome Explorer and MetaPanel diagnostic tests and a growing own-brand Invivo supplements range, with an expanding presence in Australia and the United Kingdom healthcare markets.
Average Trading Volume: 259,775
Technical Sentiment Signal: Sell
Current Market Cap: A$44.15M
Learn more about MAP stock on TipRanks’ Stock Analysis page.